Facebook
Twitter
LinkedIn
Forward
Optimal Diagnosis and Treatment of Blepharoptosis (Archived Online CME Monograph)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Blepharoptosis is a common but easily overlooked condition that has adverse effects on visual function and quality of life. In this educational activity, based on the proceedings of a live symposium, expert ophthalmologists will review the common causes of blepharoptosis and therapies for blepharoptosis correction through discussion and several real-world cases. The desired results of this activity are for participants to be better able to correctly identify the type of blepharoptosis among their patients and to select the most appropriate treatment course for correction.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate lid evaluation for blepharoptosis into routine office visits
- Describe the types of acquired blepharoptosis
- Review clinical data on the pharmacologic treatment options for blepharoptosis
- Select the appropriate treatment course for a variety of patients with acquired blepharoptosis
Faculty
 | Jason Bacharach, MD (Chair) Medical and Research Director North Bay Eye Associates, Inc Sonoma County, California Co-Director, Glaucoma Service Department of Ophthalmology California Pacific Medical Center Pacific Vision Eye Institute San Francisco, California |
 | Michael S. Korenfeld, MD, ACOS President Comprehensive Eye Care, Ltd Washington, Missouri |
 | Wendy W. Lee, MD, MS Professor of Clinical Ophthalmology and Dermatology Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Jason Bacharach, MD, is a consultant for Aerie Pharmaceuticals, Inc, Allergan, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Eyevance, Glaukos Corporation, Imprimis Pharmaceuticals, Inc, Injectsense, Inc, IRIDEX Corporation, Kala Pharmaceuticals, New World Medical, Inc, Ocular Therapeutix, Inc, Omeros Corporation, Osmotica Pharmaceuticals plc, RVL Pharmaceuticals, Inc, Santen Inc, Topcon Medical Systems, Inc, Vertical Pharmaceuticals, LLC, and Zeiss; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Allergan, Bausch & Lomb Incorporated, IRIDEX Corporation, Osmotica Pharmaceuticals plc, RVL Pharmaceuticals, Inc, Sight Sciences, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Aerpio Therapeutics, Allysta Pharmaceuticals, Inc, Biorasi, Equinox, EyePoint Pharmaceuticals, Formosapharma Pharmaceutical Inc, Glaukos Corporation, InSite Vision Inc, Kala Pharmaceuticals, Lexitas Pharma Services Inc, Nicox, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oculis, Oculos, Ocuphire Pharma, Ora, Inc, Orasis Pharmaceuticals, Perrigo Company plc, Salvat, Santen Inc, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsius Pharma, and Trefoil Therapeutics, LLC; and has individual stocks or stock options in Injectsense, Inc, Osmotica Pharmaceuticals plc, and RVL Pharmaceuticals, Inc.
Michael S. Korenfeld, MD, is a consultant for EternaTear, EyeGate, EyePoint Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Osmotica Pharmaceuticals plc, and Santen Inc; is a contracted researcher for Bausch & Lomb Incorporated, Betaliq, DEL, LLC, Formosapharma Pharmaceutical Inc, Novartis Pharmaceuticals Corporation, Oculis, Ocuphire Pharma, Perrigo Company plc, Salvat, SilkTech Biopharmaceuticals, Sun Pharmaceutical Industries, Inc, Sydnexis Inc, Sylentis, Tarsius Pharma, and Viva Biotech (Shanghai) Ltd; and has individual stocks or stock options in EternaTear, EyeGate, and Orasis Pharmaceuticals.
Wendy W. Lee, MD, MS, is a consultant for Allergan, Bausch & Lomb Incorporated, Mallinckrodt, Osmotica Pharmaceuticals plc, and Revance Therapeutics, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Tony Realini, MD, is an independent contractor for Belkin Laser, New World Medical, Inc, Ocular Therapeutix, Inc, and Sight Sciences.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from RVL Pharmaceuticals, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, RVL Pharmaceuticals, Inc, or Review of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 257.2